Anzeige
Mehr »
Login
Montag, 08.03.2021 Börsentäglich über 12.000 News von 659 internationalen Medien
Mit Vollgas in die Zukunft! Taat Lifestyle zündet den News-Turbo!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 918588 ISIN: US62856A1025 Ticker-Symbol: N/A 
1-Jahres-Chart
MYMETICS CORPORATION Chart 1 Jahr
5-Tage-Chart
MYMETICS CORPORATION 5-Tage-Chart

Aktuelle News zur MYMETICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.11.20Mymetics secures Swiss grant to advance virosome-based COVID-19 vaccine7
18.11.20Mymetics Corporation: Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant494Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Mymetics, through its collaborator, the Department of Pneumology at the Inselspital...
► Artikel lesen
MYMETICS Aktie jetzt für 0€ handeln
02.11.20Mymetics Corporation: Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine354Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe...
► Artikel lesen
23.09.20Mymetics Corporation: Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine505Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective...
► Artikel lesen
11.06.20Mymetics Corporation: Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)463Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based...
► Artikel lesen
28.05.20Mymetics Corporation: Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy403Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic...
► Artikel lesen
18.05.20Mymetics Corp.: Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines309Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1